Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. - Wikidata - awgldk - TriplyDB

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.

http://www.wikidata.org/entity/Q37102182

about

Antigen-specific active immunotherapy for ovarian cancer Antigen-specific active immunotherapy for ovarian cancer The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.High EpCAM expression is linked to proliferation and lauren classification in gastric cancer.Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling Vaccine-based clinical trials in ovarian cancer.Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature.The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.The current status of immunotherapy in peritoneal carcinomatosis.Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis

P2860

Q24193567-76FD96A7-BAAC-4A0C-A3EC-0B9020D4EA6D Q24240962-FAB68C8B-C964-4512-8CE3-93BE4E7244FD Q34624096-59F18F50-7CA7-4C46-8964-F5B75B5DC0A7 Q34800662-09D69ED1-E8DA-4268-AE08-BCDFE1179805 Q35079157-C221CB27-214A-4079-83C7-4BA3A9D5B59D Q36153347-20FF2843-0284-4C7E-8681-5DB5EB58AE4D Q36402698-6565E3D4-B5FE-4AB6-96FB-9FC42CDE41CD Q37892583-AAEC4B26-40CA-45F7-9910-0F5F28250573 Q37965555-7CAF4E40-BB11-4003-A361-DA84A936F20A Q38022538-D7C7A394-0285-46EE-A9B9-AEE99CAB55CA Q38104263-A775F42D-556A-4DC8-AD9A-A1C8F7E46754 Q38830852-4F027AF6-CD44-46A1-8E25-4276247CBBEA Q42053371-04C2EBFC-7B38-4D7A-A1FA-E594B413E3F0 Q58788761-0878AFE3-D7D0-4BD9-A17A-D095B90E77FA

P2860

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.

http://www.wikidata.org/entity/Q37102182

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Induction of anti-tumor immuni ...... ith peritoneal carcinomatosis.

@en

Induction of anti-tumor immuni ...... ith peritoneal carcinomatosis.

@nl

type

label

Induction of anti-tumor immuni ...... ith peritoneal carcinomatosis.

@en

Induction of anti-tumor immuni ...... ith peritoneal carcinomatosis.

@nl

prefLabel

Induction of anti-tumor immuni ...... ith peritoneal carcinomatosis.

@en

Induction of anti-tumor immuni ...... ith peritoneal carcinomatosis.

@nl

P1433

Q37102182-CB01BCB3-6757-474B-A0F3-2BCBB943583A

P1476

Q37102182-7E4886ED-3760-49CA-AE99-159BAE7704AE

P2093

Q37102182-200911D1-9C5B-486C-8875-A3A37B24770E

Q37102182-897408AD-F870-43E0-82FF-574EE2088569

Q37102182-9974F984-E951-4CA9-B702-9A8769171DD0

Q37102182-9BEB7241-2705-4FF4-A228-31588395F11D

Q37102182-9FC13F22-2B05-495F-A570-8790FC62EC4E

Q37102182-B45BF420-868B-4DF8-ABE8-7C933C527D44

P2860

Q37102182-0490B71F-8B5D-4972-872C-406301860DE2

Q37102182-05083152-1E88-490C-861B-914C0A9B1F19

Q37102182-06383082-5B46-416C-998F-0B2920635A60

Q37102182-092856F3-69EF-43A7-AE26-1B8FEBDAFE50

Q37102182-182242BE-165B-48AA-93B3-4B5F046F9C81

Q37102182-1E475825-3674-4656-BD9A-3307537A888A

Q37102182-309620D6-BB51-4A59-825F-162BEAEA0786

Q37102182-35536825-8A2D-41A9-BF46-E381A7923EF4

Q37102182-3B3C6A1B-66CF-40E7-8D1B-DC86BF39BB4C

Q37102182-3F239360-AE4D-4EBE-803D-99050E9693D4

P2888

Q37102182-33E36358-46B6-47D8-AC15-61B4D409D5A5

P304

Q37102182-D3F36E7F-1EBA-4E19-870D-031A21E4AD7E

P31

Q37102182-6BD9856A-B566-44D3-A493-5E171445A5E2

P356

Q37102182-C4DF0C51-95C7-4B92-9B02-DEE5A46FAF65

P478

Q37102182-53DD13F9-C213-4574-8F28-BA0AF65C5489

P577

Q37102182-2A12164F-092F-454B-9F77-5B93A6C68BC5

P5875

Q37102182-D0698E79-455B-45D3-8117-3CDED7353B46

P6179

Q37102182-B1128CBA-2D7D-4F0F-9DEB-76CD623E5D19

P698

Q37102182-94AACA91-36F5-4943-84D5-663364249918

P921

Q37102182-B2B01E30-F593-45EE-A3F0-5020A85D4F18

P932

Q37102182-898E7154-7281-4E12-AE43-AD5793B2D080

P356

1756-9966-28-18

P1433

Journal of Experimental & Clinical Cancer Research

P1476

Induction of anti-tumor immuni ...... ith peritoneal carcinomatosis.

@en

P2093

Horst Lindhofer

http://www.w3.org/2001/XMLSchema#string

Karl-Walter Jauch

http://www.w3.org/2001/XMLSchema#string

Markus M Heiss

http://www.w3.org/2001/XMLSchema#string

Michael A Ströhlein

http://www.w3.org/2001/XMLSchema#string

Michael Jäger

http://www.w3.org/2001/XMLSchema#string

Robert Siegel

http://www.w3.org/2001/XMLSchema#string

P2860

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.

Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure.

Multimodal treatment of peritoneal carcinomatosis and sarcomatosis.

Peritonectomy procedures.

An overview of HER2.

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.

Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia.

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

P2888

1756-9966-28-18

P304

18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-28-18

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24010043

http://www.w3.org/2001/XMLSchema#string

P6179

1024273160

http://www.w3.org/2001/XMLSchema#string

P698

19216794

http://www.w3.org/2001/XMLSchema#string

P921

P932

2644666

http://www.w3.org/2001/XMLSchema#string